Mueller Industries (MLI) reported a year-over-year increase in fiscal Q3 adjusted diluted earnings and net sales late Monday.
Shares jumped 16%, with intraday trading volume at over 1.17 million compared with a daily average of about 777,000.
Indaptus Therapeutics (INDP) disclosed a clinical supply agreement late Tuesday with BeiGene (BGNE).
Indaptus plans to advance human clinical evaluation of a combination of BeiGene's anti-PD-1 antibody, tislelizumab, with its Decoy20, a novel treatment designed to induce a broad immune response to fight cancer. As part of the agreement, BeiGene will also provide technical expertise to accelerate the first clinical trial combining the two investigational drugs.
Shares of Indaptus advanced 16% as intraday trading volume climbed to over 4.03 million from a daily average of about 17,000.
General Motors (GM) reported a year-over-year jump in Q3 adjusted earnings and revenue, beating market expectations.
Shares jumped 9.2% as intraday trading volume surged to more than 28.1 million from a daily average of about 13.6 million.
Price: 83.72, Change: +11.64, Percent Change: +16.14
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。